Related Experiment Video

Updated: May 9, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A

R Cencic1, F Robert, G Galicia-Vázquez

  • 1Department of Biochemistry, McGill University, Montreal, Quebec, Canada.

Blood Cancer Journal
|July 23, 2013
PubMed

Insights

Hippuristanol (Hipp) resensitizes lymphomas to chemotherapy by inhibiting translation initiation factor 4A (eIF4A). Combining Hipp with ABT-737 synergistically triggers cell death in lymphoma and leukemia cells, highlighting eIF4AI as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells often hijack signaling pathways like PI3K/Akt/mTOR to regulate protein translation.
  • mTOR controls translation by influencing the eukaryotic initiation factor 4F (eIF4F) complex assembly, crucial for ribosome recruitment to mRNA.
  • Targeting eIF4F offers a strategy to impact tumor growth and chemotherapy response.

Purpose of the Study:

  • To investigate the therapeutic potential of hippuristanol (Hipp), a selective eIF4A inhibitor, in sensitizing lymphomas to DNA damaging agents.
  • To evaluate the synergistic effect of combining Hipp with a Bcl-2 family inhibitor (ABT-737) on lymphoma and leukemia cell death.
  • To identify eIF4AI as a potential therapeutic target for enhancing chemotherapy efficacy.

Main Methods:

  • Treatment of Eμ-Myc lymphomas with hippuristanol (Hipp) and DNA damaging agents.
  • Assessment of Mcl-1 levels following Hipp treatment.
  • Combination therapy using Hipp and ABT-737 in mouse and human lymphoma/leukemia cells.
  • RNA interference to suppress eIF4AI in murine lymphomas.

Main Results:

  • Hippuristanol resensitized lymphomas, including those overexpressing eIF4E, to DNA damaging agents.
  • Hippuristanol significantly affected Mcl-1 levels.
  • The combination of Hipp and ABT-737 induced potent synergistic cell death in various lymphoma and leukemia cells.
  • Suppression of eIF4AI via RNA interference also synergized with ABT-737 in murine lymphomas.

Conclusions:

  • Hippuristanol shows promise in resensitizing tumors to chemotherapy by targeting translation initiation.
  • Combining eIF4A inhibition with Bcl-2 inhibition offers a potent synergistic strategy for inducing cancer cell death.
  • eIF4AI represents a viable therapeutic target for improving responses to chemotherapy in lymphomas and leukemias.

More Related Videos

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death13:54

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death

Published on: October 21, 2012

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...